Gilead Sciences vs Vertex Pharmaceuticals
Gilead Sciences reported revenue of $29.4 billion in fiscal 2025, 2.5 times Vertex Pharmaceuticals' $12.0 billion in fiscal 2025. Gilead Sciences' revenue grew 2.4% in its latest year, and Vertex Pharmaceuticals' grew 8.9%. Gilead Sciences had an operating margin of 34.0%, against 34.8% at Vertex Pharmaceuticals. Free cash flow was $9.5 billion at Gilead Sciences and $3.2 billion at Vertex Pharmaceuticals.
Side by side
| Gilead Sciences | Vertex Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $29.4B | $12.0B |
| Revenue growth | 2.4% | 8.9% |
| Revenue growth a year, last 5 years | 3.6% | 14.1% |
| Gross margin | 78.8% | 86.2% |
| Operating margin | 34.0% | 34.8% |
| Net margin | 28.9% | 32.9% |
| Free cash flow | $9.5B | $3.2B |
| Free cash flow margin | 32.1% | 26.6% |
| Return on capital | 22.9% | 31.5% |
| Net debt to EBITDA | 1.4x | −1.5x |
| Dividends and buybacks | $5.9B | $2.0B |
| Change in diluted share count | 0.0% | 0.0% |
| Last close | $158.69 | $517.49 |
| P/E at the last close | — | 30.1× |
| Insider trades, last 12 months | sold $85.8 million | sold $158.1 million |
| Piotroski F-score | 8 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Gilead SciencesVertex Pharmaceuticals
Operating margin
Percent of revenue
Gilead SciencesVertex Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Gilead SciencesVertex Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Gilead Sciences and Vertex Pharmaceuticals pages.